Drugs / Armour Thyroid
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04124705 | Oct 2019 → Jun 2021 | hypothyroidism | Allergan | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06345339 | Apr 2024 → Sep 2027 expected | hypothyroidism | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Armour Thyroid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06345339 ↗ |
| Route | Oral | “Administered orally once a day.” NCT04124705 ↗ |